Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 1/20 | 0.38 |
| ▸ | MAOB | P27338 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 2/20 | 0.36 |
| ▸ | TACR1 | P25103 | 2/20 | 0.36 |
| ▸ | TACR3 | P29371 | 2/20 | 0.36 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.36 |
| ▸ | AR | P10275 | 1/20 | 0.36 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.35 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.35 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | ELANE | P08246 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3524295 | 1.00 | MAOA (0.38) | MAOAMAOBLMNATSHRTACR1 | |
| SCHEMBL6297140 | 0.86 | HTT (0.35) | MAOBHSD11B1NR3C2 | |
| SCHEMBL6303554 | 0.84 | LMNA (0.40) | LMNANR3C2MEN1KMT2A | |
| SCHEMBL4608649 | 0.83 | DDB1 (0.50) | DDB1CRBN | |
| SCHEMBL6297349 | 0.77 | DDB1 (0.44) | DDB1CRBNKMT2A | |
| SCHEMBL13589960 | 0.74 | CYP2C19 (0.35) | LMNATSHRHSD11B1 | |
| SCHEMBL10027901 | 0.74 | CYP2C19 (0.35) | LMNATSHRHSD11B1 | |
| SCHEMBL5798686 | 0.74 | PPARG (0.40) | — | |
| SCHEMBL6299105 | 0.73 | MAOA (0.40) | MAOAMAOBLMNANR3C1DDB1 | |
| SCHEMBL8261141 | 0.73 | MMP9 (0.45) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7807677-B2 | HIV protease inhibitors | MEDIVIR AB (SE) | 2010-10-05 | — | — | US | disclosed |
| EP-1851193-B1 | HIV PROTEASE INHIBITORS | MEDIVIR AB (SE) | 2009-04-22 | — | — | EP | disclosed |
| US-20080249102-A1 | Hiv Protease Inhibitors | MEDIVIR AB (SE) | 2008-10-09 | — | — | US | disclosed |
| EP-1851193-A1 | HIV PROTEASE INHIBITORS | MEDIVIR AB (SE) | 2007-11-07 | — | — | EP | disclosed |
| WO-2006084688-A1 | HIV protease inhibitors | MEDIVIR AB (SE) | 2006-08-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080249102-A1 | Hiv Protease Inhibitors | SERPINB1, ANPEP, XPNPEP1 | MAOA 475/4885MAOB 890/4885LMNA 534/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.